Market Overview

Why JMP Securities Is Watching (And Loving) These 3 Biotech Stocks


In a report published Tuesday, JMP Securities named three biotech stocks it is watching: Acceleron Pharma Inc (NASDAQ: XLRN), Cardiovascular Systems Inc (NASDAQ: CSII) and Karyopharm Therapeutics Inc (NASDAQ: KPTI).

Acceleron’s (Market Outperform, $52 price target) early stage clinical results at ASCO Genitourinary(GU) 2015 “support a positive outlook for maturing PFS results while providing encouragement for ongoing later stage development.”

According to analyst Michael G. King, the data is “not only encouraging because of the continued exceptional overall response rate (ORR) of 25% described in the abstract, but also because of the insight into the expected progression free survival of the fully mature Part I dataset.”

Cardiovascular Systems (Market Outperform, $44 price target) on Monday released its two-year data from its ORBIT II study of the Diamondback 360 Coronary Orbital Atherectomy System (OAS) in treating severely calcified lesions.

“The new data reaffirms that CSI’s orbital atherectomy technology is a safe and effective treatment option for severely calcified arteries. The MACE rate at two years was 19.8%, up only slightly from 16.4% at one year. MI rates remained unchanged at 9.7%. We are encouraged by these positive clinical results and believe that they will continue to drive adoption of orbital atherectomy in the coronary setting.”

Karyopharm (Market Outperform, $57 price target) recently published data “demonstrating the reduction of disease progression in two separate mouse models of multiple sclerosis with two Selective Inhibitors of Nuclear Export (SINE) compounds of exportin 1 (XPO-1). This decrease was attributed to two main mechanisms by the SINE compounds: a) via reduction of neuronal inflammation; and b) by prevention of toxic factors in the brain from causing damage to the neuronal myelin coating.”

According to King, “these data highlight a meaningful and potential clinical opportunity for the oral drug KPT-350 that is currently in development for inflammatory and autoimmune diseases; and specifically, for multiple sclerosis (MS) patients who are averse to infusions or injections with leading treatments on the market, such as Avonex (BIIB, NC) or Copaxone (TEVA, NC) or are unable to tolerate the GI issues that may be associated with an oral drug like Tefcidera (BIIB, NC).”

Latest Ratings for XLRN

Feb 2019Cowen & Co.Initiates Coverage OnOutperform
Sep 2018PiperJaffrayUpgradesNeutralOverweight
Sep 2018Morgan StanleyAssumesEqual-Weight

View More Analyst Ratings for XLRN
View the Latest Analyst Ratings

Posted-In: ASCO Genitourinary ASCO GU AvonexAnalyst Color Health Care Reiteration Analyst Ratings General


Related Articles (CSII + KPTI)

View Comments and Join the Discussion!

Latest Ratings

INTUMorgan StanleyMaintains245.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Trader Essentials
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

UPDATE: First Solar Posts Higher Q4 Earnings, Misses Revenue Views

Rio Tinto 'Top Pick' For Canaccord